{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"126","value":"157"},{"groupId":"OG001","spread":"96.7","value":"103"},{"groupId":"OG002","spread":"159","value":"219"},{"groupId":"OG003","spread":"200","value":"166"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"43"}],"units":"Participants"}],"description":"Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.","dispersionType":"Standard Deviation","groups":[{"description":"PCI-32765 420 mg per day\n\nPCI-32765","id":"OG000","title":"Cohort 1"},{"description":"PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"OG001","title":"Cohort 2"},{"description":"PCI-32765 840 mg per day\n\nPCI-32765","id":"OG002","title":"Cohort 3"},{"description":"PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"OG003","title":"Cohort 4"}],"paramType":"MEAN","populationDescription":"All subjects who received at least one dose of study treatment and had evaluable pharmacokinetic data.","reportingStatus":"POSTED","timeFrame":"Procedure was performed up to 60 weeks.","title":"Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"ng/mL"}